Search the Community
Showing results for tags 'tok-001'.
Trial stopped - see below. Men who are on androgen deprivation therapy and who have metastases may be interested in the following Phase 3 clinical trial: A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC (ARMOR3-SV) Details of this trial are available at XXXXXXXXX To be eligible, you must not have been treated with abiraterone, enzalutamide or chemotherapy. You must have detectable AR-V7 (your circulating tumour cells will be tested as part of the eligibility process).
Trial stopped - see below Thanks for Chuck Maack for alerting us to this. Galeterone (TOK-001) is a highly selective, multi-targeted, oral small molecule, drug candidate for the treatment of prostate cancer that disrupts androgen receptor (AR) signalling, the key driver of prostate cancer growth, via multiple mechanisms of action: androgen receptor degradation, which reduces the amount of androgen receptor protein in the tumor cells; inhibition of the enzyme CYP17, which blocks the synthesis of testosterone; and androgen receptor antagonism, which blocks th